Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Sorrento Therapeutics’ oral Mpro inhibitor olgotrelvir has hit the primary endpoint and a key secondary endpoint in a Phase III trial that recruited adults with mild-to-moderate Covid. Subsequently, the company has reached out to China’s NMPA with an eye to submitting an NDA for expedited review.
In the phase 3 trial, a randomized double blind and placebo-controlled pivotal study, 1,212 mild or moderate COVID-19 patients were enrolled and treated with OVYDSO„¢ (Olgotrelvir) or placebo. The...
All study objectives were met, demonstrating safety across dose groups and confirming efficacy and durability at the selected doses against placebo (lidocaine) and active control (steroid).All RTX...
Abivertinib is a novel Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly targets BTK. BTK inhibitors are a large category in cancer treatment, with multiple indications and generating over...
The Phase 3 study of Ovydso was initiated in China in February 2023 and enrolled and dosed 1,200 COVID-19 patients (1:1, active:placebo) at 25 sites in China.During the trial, Ovydso has maintained an...